Note:


we have news on one of our patents... YYYIIIIIIIIIIPEEEEEEEEEEEEE

7 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06


read the link

Lilly Highlights Two Collaboration Drugs in Its Pipeline Update
PR Newswire (press release), NY - 22 hours ago
- Plans Broad Phase 2 Cancer Trials for Survivin ASO to Begin Late in 2006 and 2007 - CARLSBAD, Calif., Dec. 11 /PRNewswire-FirstCall ...

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=


Look at patent list for Eirx re: SURVIVIN patent number 7

http://v3.espacenet.com/results?sf=a&FIRST=1&CY=gb&LG=en&DB=EPODOC&TI=&AB=&PN=&AP=&PR=&PD=&PA=eirx&IN=&EC=&IC=&=&=&=&=&=

hello hello hello.. I think something has leaked ;-)


Breast Cancer : A New Preclinical Research Tool
Main Category: Breast Cancer News
Article Date: 14 Jul 2007 - 0:00 PDT

email to a friend printer friendly view / write opinions rate article newsletters


Latest News For This Category
Further Light Shed On The Mechanisms Regulating ER-Alpha Expression Levels During Breast Cancer
16 Jul 2007
Women With Breast Cancer Carrying BRCA Genetic Mutations Have Similar Survival, Death Rates As Noncarriers, Study Says
16 Jul 2007

At the Institut Curie, Inserm researchers and physicians have established the largest ever panel of human breast cancer xenografts in animal models. Because of their similarity to patient tumors, these models are an exceptional tool for testing the efficacy of new drugs, adapting treatments to tumor characteristics, unraveling resistance to certain treatments, and as a result limiting the need for clinical trials in patients. Institut Curie and Inserm medical oncologists, surgeons, pathologists and biologists collaborated on this work on mouse models which can now be extended to other types of cancers. The 25 breast tumor models are described in a study published in the 1 July 2007 issue of Clinical Cancer Research.

To help clinicians in their search for more effective treatments, Marie-France Poupon and her team in Institut Curie Inserm Unit 612 "Genotoxicology, signaling and experimental radiotherapy" have developed the largest ever series of human breasts cancers grafted into mice. This six-year study would not have been successful without close collaboration between Institut Curie and Inserm medical oncologists, surgeons, pathologists, and biologists.

These breast cancer xenografts in mice reproduce the genetic, genomic, and histological characteristics of the patient-derived tumor tissues. So they recapitulate features of the original tumors, such as overexpression of HER2 receptors, absence or presence of estrogen receptors, mutation of P53, and react identically to chemotherapy.

Twenty-five models of breast tumors in mice of different biological profiles have been established. These models are an excellent preclinical research tool and can be used to test the efficacy of new drugs and novel therapeutic combinations, as well as analyze the response to treatment and adapt it to the tumor characteristics. This will help in the design of clinical trials and hasten the development of new treatments.

This work is continuing within the framework of the creation of a Preclinical Investigation Laboratory in the Translational Research Department at the Institut Curie, with a view to extending this series of tumor models to other types of cancers, such as pediatric cancers, melanoma, lung cancer, ovarian cancer, and cancers of the bronchi, prostate, and colon.

Breast cancer

Breast cancer is the most frequent cancer in women and affects one in ten women in the developed world. Every year in France there are 42 000 new cases. Between 1980 and 2000, the number of cases increased by almost 60%, largely as a result of increasingly efficient detection and because people are living longer. Breast cancer is most commonly detected in women aged between 50 and 69 years of age (half of all cases), but can occur at any age, albeit very rarely before the age of 25. Mortality has declined because of earlier detection and improved treatments combining surgery, radiotherapy, and chemotherapy, depending on the tumor characteristics. When the diagnosis is made early enough, conservative surgery is possible: the tumor is removed and the breast conserved. When the tumor is larger, or is accompanied by extensive precancerous lesions, it is sometimes essential to remove the breast (mastectomy).

INSTITUT CURIE
26, rue d'Ulm
75005 Paris Cedex 05
http://www.curie.fr

are we going to be millionaires

hope so

MGI Pharam webcast tonight.. so should get an update on how ZYC300 is progressing

On the subject of finance, EiRx will be at the Ireland-Europe BioPartnering 2007 conference on 21 November 2007, see the following link for company profiles and agenda:

http://www.biotechnologyireland.com/pooled/articles/BF_EVENTART/view.asp?Q=BF_EVENTART_293930

They clearly intend to be in business then, so this bust next week talk, I'm afraid is incorrect.

By the way, if anyone is in Dublin on that day, you can sign up to meet EiRx and hear them talk.

.